|
1
|
Amara CS, Vantaku V, Lotan Y and Putluri
N: Recent advances in the metabolomic study of bladder cancer.
Expert Rev Proteomics. 16:315–324. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lenis AT, Lec PM, Chamie K and Mshs MD:
Bladder cancer: A review. JAMA. 324:1980–1991. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rouprêt M, Babjuk M, Burger M, Capoun O,
Cohen D, Compérat EM, Cowan NC, Dominguez-Escrig JL, Gontero P,
Hugh Mostafid A, et al: European association of urology guidelines
on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol.
79:62–79. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
He A, He S, Peng D, Zhan Y, Li Y, Chen Z,
Gong Y, Li X and Zhou L: Prognostic value of long non-coding RNA
signatures in bladder cancer. Aging (Albany NY). 11:6237–6251.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dal Moro F, Valotto C, Guttilla A and
Zattoni FJU: Urinary markers in the everyday diagnosis of bladder
cancer. Urologia. 80:265–275. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bellmunt J, Valderrama BP, Puente J,
Grande E, Bolós MV, Lainez N, Vázquez S, Maroto P, Climent MÁ,
Garcia Del Muro X, et al: Recent therapeutic advances in urothelial
carcinoma: A paradigm shift in disease management. Crit Rev Oncol
Hematol. 174:1036832022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Husain A, Chiu YT, Sze KM, Ho DW, Tsui YM,
Suarez EMS, Zhang VX, Chan LK, Lee E, Lee JM, et al:
Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to
enhance cancer stemness in hypoxic hepatocellular carcinoma. J
Hepatol. 77:383–396. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen J: Regulation of tumor initiation and
metastatic progression by Eph receptor tyrosine kinases. Adv Cancer
Res,. 114:1–20. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Deng M, Tong R, Zhang Z, Wang T, Liang C,
Zhou X and Hou G: EFNA3 as a predictor of clinical prognosis and
immune checkpoint therapy efficacy in patients with lung
adenocarcinoma. Cancer Cell Int. 21:5352021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zheng P, Liu X, Li H, Gao L, Yu Y, Wang N
and Chen H: EFNA3 is a prognostic biomarker correlated with immune
cell infiltration and immune checkpoints in gastric cancer. Front
Genet,. 12:7965922022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang L, Song Y, Wang H, Liu K, Shao Z and
Shang Z: MiR-210-3p-EphrinA3-PI3K/AKT axis regulates the
progression of oral cancer. J Cell Mol Med. 24:4011–4022. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Blum A, Wang P and Zenklusen JC: SnapShot:
TCGA-Analyzed Tumors. Cell. 173:5302018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chandrashekar DS, Karthikeyan SK, Korla
PK, Patel H, Shovon AR, Athar M, Netto GJ, Qin ZS, Kumar S, Manne
U, et al: UALCAN: An update to the integrated cancer data analysis
platform. Neoplasia. 25:18–27. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
World Medical Association, . World Medical
Association Declaration of Helsinki: Ethical principles for medical
research involving human subjects. JAMA. 310:2191–2194. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stephenson AJ, Wood DP, Kattan MW, Klein
EA, Scardino PT, Eastham JA and Carver BS: Location, extent and
number of positive surgical margins do not improve accuracy of
predicting prostate cancer recurrence after radical prostatectomy.
J Urol. 182:1357–1363. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Expert Panel on Urological Imaging, .
Allen BC, Oto A, Akin O, Alexander LF, Froemming AT, Fulgham PF,
Halpern DJ, Gettle LM, Maranchie JK, et al: ACR Appropriateness
Criteria® Post-Treatment Surveillance of Bladder Cancer: 2021
Update. J Am Coll Radiol. 18((5S)): S126–S138. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bhuvaneswari R, Gan YY, Lucky SS, Chin WW,
Ali SM, Soo KC and Olivo M: Molecular profiling of angiogenesis in
hypericin mediated photodynamic therapy. Mol Cancer. 7:562008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu J, Xie RY, Cao CZ, Shang BQ, Shi HZ and
Shou JZ: Disease management of clinical complete responders to
neoadjuvant chemotherapy of muscle-invasive bladder cancer: A
review of literature. Front Oncol. 12:8164442022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nievergall E, Lackmann M and Janes PW:
Eph-dependent cell-cell adhesion and segregation in development and
cancer. Cell Mol Life Sci. 69:1813–1842. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gomez-Maldonado L, Tiana M, Roche O,
Prado-Cabrero A, Jensen L, Fernandez-Barral A, Guijarro-Muñoz I,
Favaro E, Moreno-Bueno G, Sanz L, et al: EFNA3 long noncoding RNAs
induced by hypoxia promote metastatic dissemination. Oncogene.
34:2609–2620. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang H, Wang L, Zhou X, Luo X, Liu K,
Jiang E, Chen Y, Shao Z and Shang Z: OSCC exosomes regulate
miR-210-3p Targeting EFNA3 to promote oral cancer angiogenesis
through the PI3K/AKT Pathway. Biomed Res Int.
2020:21256562020.PubMed/NCBI
|
|
23
|
Besnier M, Gasparino S, Vono R, Sangalli
E, Facoetti A, Bollati V, Cantone L, Zaccagnini G, Maimone B,
Fuschi P, et al: miR-210 enhances the therapeutic potential of
bone-marrow-derived circulating proangiogenic cells in the setting
of limb ischemia. Mol Ther. 26:1694–1705. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Catez F, Dalla Venezia N, Marcel V, Zorbas
C, Lafontaine DLJ and Diaz JJ: Ribosome biogenesis: An emerging
druggable pathway for cancer therapeutics. Biochem Pharmacol.
159:74–81. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pelletier J, Thomas G and Volarević S:
Ribosome biogenesis in cancer: New players and therapeutic avenues.
Nat Rev Cancer. 18:51–63. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Enokida H and Nakagawa M: Epigenetics in
bladder cancer. Int J Clin Oncol. 13:298–307. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Awadalla A, Abol-Enein H, Hamam ET, Ahmed
AE, Khirallah SM, El-Assmy A, Mostafa SA, Babalghith AO, Ali M,
Abdel-Rahim M, et al: Identification of epigenetic interactions
between miRNA and gene expression as potential prognostic markers
in bladder cancer. Genes (Basel). 13:16292022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Abdou AG, Abd el-Wahed MM, Asaad NY,
Samaka RM and Abdallaha R: Ephrin A4 expression in osteosarcoma,
impact on prognosis, and patient outcome. Indian J Cancer.
47:46–52. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lorenzatti Hiles G, Bucheit A, Rubin JR,
Hayward A, Cates AL, Day KC, El-Sawy L, Kunju LP, Daignault S, Lee
CT, et al: ADAM15 is functionally associated with the metastatic
progression of human bladder cancer. PLoS One. 11:e01501382016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kataoka A, Yamada K, Hagiwara T, Terayama
M, Sugimoto T, Nohara K, Igari T, Yokoi C and Kawamura YI:
Expression status of serine protease 27: A prognostic marker for
esophageal squamous cell carcinoma treated with preoperative
chemotherapy/chemoradiotherapy. Ann Surg Oncol. 28:5373–5381. 2021.
View Article : Google Scholar : PubMed/NCBI
|
